• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Miach Orthopaedics makes ACL tear implant commercially available in U.S.

Miach Orthopaedics makes ACL tear implant commercially available in U.S.

December 1, 2021 By Sean Whooley

Miach OrthopaedicsMiach Orthopaedics announced today that it made the BEAR implant for treating anterior cruciate ligament (ACL) tears commercially available in the U.S.

Westborough, Massachusetts–based Miach designed the BEAR (Bridge-Enhanced ACL Restoration) implant to enable the healing of a patient’s torn ACL, shifting from the current standard of care that includes reconstruction that replaces the ACL with a graft.

According to a news release, the BEAR implant also received a Popular Science Best of What’s New Award for its representation of a significant step forward in health.

The BEAR implant restores ACL quality and size similar to the non-injured ACL to provide faster recovery of muscle strength and better patient satisfaction around returns to sports. By eliminating the need for a graft, BEAR allows for patients to avoid needing a second wound site to heal and alleviates worries about donor graft quality or risk of disease.

Dr. Jonathan L. Glashow, the Chief Medical Advisor for the New Jersey Devils (National Hockey League) and Philadelphia 76ers (National Basketball Association), and Dr. Thom Mayer, Medical Director for the National Football League Players Association, both expressed encouragement over the benefits of the BEAR implant.

“ACL tears are a common sports injury, no matter what you play or at what level, and they can be devastating for our players in the NFL,” Mayer said in the release. “As a new treatment option with exciting benefits over traditional ACL reconstruction, I’m hopeful that the BEAR Implant can help people return to the sports and activities they love.”

A torn ACL does not heal on its own, making ACL reconstruction one of the most common orthopedic procedures in the U.S., Miach said, with approximately 400,000 ACL injuries occurring per year in the country.

“We’ve been overwhelmed by the interest from patients who’ve torn their ACLs and are actively seeking an alternative to the current standard of care,” Miach Orthopaedics President & CEO Martha Shadan said. “We’re honored the BEAR Implant was selected by Popular Science as one of the best new health products of the year, and we are excited to make this innovative treatment available for patients.”

Filed Under: Business/Financial News, Featured, Implants, News Well, Orthopedics Tagged With: Miach Orthopaedics, Miach Orthopedics

More recent news

  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes
  • FDA posts alert for Edwards Lifesciences mitral valve delivery system after patient death
  • Former Medtronic RDN leader joins Teleflex
  • CMR Surgical CEO outlines the path forward for Stryker’s robotics partnership
  • Stryker earns FDA clearance for new bone and soft tissue removal platform

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy